Vilus Jean Taj, Engelhard Caitlin
Pediatr Ann. 2025 Jan;54(1):e27-e33. doi: 10.3928/19382359-20241007-07. Epub 2025 Jan 1.
Attention-deficit/hyperactivity disorder (ADHD) is one of the most common pediatric psychiatric disorders and is frequently diagnosed and treated by pediatricians. Stimulant medications are the first-line treatment for ADHD but may not be a good fit for many patients due to side effects, inadequate treatment response, or family preference. Non-stimulant ADHD medications provide a useful alternative for patients that cannot tolerate stimulants, have an incomplete treatment response to stimulants, are at risk for stimulant diversion, or whose family prefers to avoid stimulants. Nonstimulant ADHD medications can be used as monotherapy or added to a stimulant as an augmentation strategy. The recommended nonstimulant ADHD medications include alpha agonists (eg, guanfacine extended-release [ER], clonidine ER) and norepinephrine reuptake inhibitors (eg, atomoxetine, viloxazine). Other nonstimulant medications (eg, buproprion, tricyclic antidepressants, polyunsaturated fatty acids) have been used off-label for ADHD but are not recommended and should only be considered as a third-line option. .
注意缺陷多动障碍(ADHD)是最常见的儿科精神疾病之一,儿科医生经常对其进行诊断和治疗。兴奋剂药物是治疗ADHD的一线药物,但由于副作用、治疗反应不充分或家庭偏好等原因,可能并不适合许多患者。非兴奋剂ADHD药物为无法耐受兴奋剂、对兴奋剂治疗反应不完全、有兴奋剂滥用风险或其家庭倾向于避免使用兴奋剂的患者提供了一种有用的替代选择。非兴奋剂ADHD药物可作为单一疗法使用,或作为增效策略添加到兴奋剂中。推荐的非兴奋剂ADHD药物包括α受体激动剂(如缓释胍法辛、缓释可乐定)和去甲肾上腺素再摄取抑制剂(如托莫西汀、维洛沙嗪)。其他非兴奋剂药物(如安非他酮、三环类抗抑郁药、多不饱和脂肪酸)已被超说明书用于治疗ADHD,但不推荐使用,仅应作为三线选择考虑。